Intracranial Arteriosclerosis
3
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
3
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Neurotech PharmaceuticalsRI - Cumberland
1 program1
Experimental Device A, a self-expanding rapamycin target-eluting stentPhase 31 trial
Active Trials
MicroPortChina - Shanghai
1 program1
Experimental Device A, a self-expanding rapamycin target-eluting stentPhase 3
Trial Timeline
Clinical trial activity over time
2022
2023
2024
2025
2026
2027
Neurotech PharmaceuticalsExperimental Device A, a self-expanding rapamycin target-eluting stent
AstraZenecaTicagrelor + Aspirin
Clinical Trials (2)
Total enrollment: 1,962 patients across 2 trials
NCT06925971Neurotech PharmaceuticalsExperimental Device A, a self-expanding rapamycin target-eluting stent
A Randomized Trial of the Rapamycin Target Eluting Stent for the Treatment of Symptomatic Cerebral Artery Atherosclerotic Disease（TARGET-DREAM）
Start: Apr 2025Est. completion: Oct 2027279 patients
Phase 3Not Yet Recruiting
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
Start: Aug 2022Est. completion: Jan 20271,683 patients
Phase 3Active Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.